Article Versions Notes

Ismail T, Alzneika S, Riguene E, Al-maraghi S, Alabdulrazzak A, Al-Khal N, Fetais S, Thanassoulas A, AlFarsi H, Nomikos M. BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer. Pharmaceuticals. 2024; 17(3):333. https://doi.org/10.3390/ph17030333

Ismail, Tala, Safa Alzneika, Emna Riguene, Salwa Al-maraghi, Aya Alabdulrazzak, Noof Al-Khal, Sara Fetais, Angelos Thanassoulas, Halema AlFarsi, and Michail Nomikos. 2024. "BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer" Pharmaceuticals 17, no. 3: 333. https://doi.org/10.3390/ph17030333

Ismail, T., Alzneika, S., Riguene, E., Al-maraghi, S., Alabdulrazzak, A., Al-Khal, N., Fetais, S., Thanassoulas, A., AlFarsi, H., & Nomikos, M. (2024). BRCA1 and Its Vulnerable C-Terminal BRCT Domain: Structure, Function, Genetic Mutations and Links to Diagnosis and Treatment of Breast and Ovarian Cancer. Pharmaceuticals, 17(3), 333. https://doi.org/10.3390/ph17030333